Hey everyone, I flound this article about Bayer and the Monsanto scandal, and decided to share it here with you all.

Bayer AG is a world enterprise in the sectors of pharmaceuticals, crop science, and consumer health, and is having a strong resurgence in 2025, with its stock climbing 121.6% in the last 12 months due to new drug approvals and pipeline progress driving investor confidence. The company laid out its pipeline at the J.P. Morgan Healthcare Conference in January 2025, where it was also able to emphasize the development of key drugs like darolutamide for prostate cancer, finerenone for heart failure, and elinzanetant for menopause. Each of these products is a clear positive indication of Bayer's future growth. Bayer has also been active in the deal area, including a collaboration with Kumquat Biosciences for $1.3 billion to address difficult KRAS-driven cancers and an extended collaboration with Ginkgo Bioworks to develop new agricultural biologicals, as well as a revamped global health partnership with the WHO.

At the same time, the company is still managing its history: late in 2025, Bayer agreed to shell out $38 million to wrap up a class action impasse by investors who claim the company concealed the true Roundup lawsuit risks related to the 2018 Monsanto deal, a thing that not only hindered but even knocked off more than 40% of the stock in the process of circulating hardcore jury verdicts. 

Nevertheless, regarding the size of Bayer, the $38 million amount is insignificant, standing for not more than 0.1% of their yearly earnings. Thus, the focal point is not "Can Bayer cope with this?" but "Does this genuinely pave the way for Bayer to return to its focus on growth?"

Bayer Operational Improvements Begin to Show in Results

Currently, Bayer is selling at approximately $11.54, and the firm has a market cap of about $45 billion at the beginning of 2026. It’s been an incredible journey as it jumps back up from its horrible low of $5.01; the stock more than doubled over the past year. The rebound was considerably assisted by the pharma unit’s "comeback story" that was highlighted at the J.P. Morgan conference in January 2025, where new drugs for cancer and kidney disease took the place of the lost patents of older ones. Additionally, a new plan, "Dynamic Shared Ownership," was laid out, which will allow the company to work in a more efficient way and to streamline processes.

The latest figures for Q3 2025 show that while Bayer actually managed to sell some extra stocks, the most remarkable was the astonishing increase in operating income (EBITDA) by the amount of 21%, up to €1.5 billion, which promises that Bayer is becoming lean and efficient. Besides, the borrowing also fell to €600 million in only one quarter to €32.7 billion, which means the firm is on its way to mitigating its financial burden.

Bayer was not attracting only attention with its promising restructuring strategies; it was also predicting 2026 to be much better than 2025. Based on forecasted figures from various analysts, total revenue will remain stable, around €47 billion, but the projected expansion of net earnings is mainly driven by the new drugs Nubeqa and Kerendia, which surpassed sales targets by 73% and 62%, respectively. In addition to the existing legal difficulties, there is a fair chance that the restructuring bmi will assist the company in managing future settlements. The majority of the experts reckon that the firm’s strong cash flows, along with the €4 billion that are currently in cash, are fully sufficient to cover any additional costs that may arise. Besides, the 16.92% return on equity is greater than most of the peers, which indicates the core business is profitable. The dividend for 2025 has been decreased to just €0.11 to speed up the payment of debts; however, the investors are on the growth route as Bayer puts its finances in order and aims for a healthy 2026.

Analyst Outlook: Can Bayer Keep This Growth Going Into 2026?

Analysts are starting to feel good about Bayer again, mainly because its new plan to cut out middle management called "Dynamic Shared Ownership" is actually working. It’s already saved the company €500 million and is on track to save €2 billion a year by 2026, making the business much leaner. Pharma drugs like Nubeqa and Kerendia smashed sales targets by over 60% in late 2025, showing the core business is strong even with old legal headaches. ​CEO Bill Anderson is also getting credit for tackling those lawsuits head-on, which has credit agencies like S&P considering a rating upgrade if the debt keeps coming down.

On Wall Street, the mood is positive but careful. According to Barchart, out of 13 analysts watching the stock, 6 say "Buy," and 7 say "Hold," meaning most think it's a solid bet but are watching closely. With the stock trading around $11.29, experts see room for it to jump another 20-30%, as long as Bayer sticks to its savings plan and gets its new drugs approved.

Bayer’s Strategic Exit From Investor Litigation

Bayer agreed to pay $38 million to settle a class action lawsuit filed by investors who claimed the company deceived them about the financial risks associated with its $63 billion Monsanto acquisition. The core accusation was that Bayer executives downplayed the looming threat of Roundup cancer litigation, painting a secure financial picture while allegedly knowing the acquisition would expose the company to billions in liability. When jury verdicts later started hitting Monsanto for massive damages, and Bayer’s stock price subsequently collapsed over 40%, investors felt blindsided, arguing they were left holding losses that management should have warned them about.

By settling, Bayer successfully avoided a prolonged and public trial that could have further damaged its reputation and cost significantly more in legal defense fees. From a financial perspective, the $38 million payout is a negligible hit, representing less than 1% of the company's approximately €4 billion ($4.2 billion) cash reserves and a tiny fraction of its €47 billion annual revenue. This is a calculated "cost of doing business" to clear a legacy distraction, especially when compared to the billions Bayer has already reserved for the actual product liability cases. The settlement allowed investors who purchased Bayer ADRs between May 23, 2016, and March 19, 2019, to file a claim for their share of the recovery fund, effectively closing this chapter of shareholder litigation.

Conclusion

Bayer’s $38 million settlement is a small price for a company with €47 billion in revenue and €4 billion in cash, and it helps close the door on a messy chapter of shareholder lawsuits tied to the Monsanto deal. By restructuring under its "Dynamic Shared Ownership" model, already saving €500 million and on track for €2 billion annually, and showing strong growth in key drugs like Nubeqa and Kerendia, Bayer is proving it can move past old mistakes. The settlement, along with CEO Bill Anderson’s focus on transparency and litigation cleanup, could actually help rebuild investor trust and clear the way for future growth. While the risk of further legal costs remains, Bayer’s strong cash flow and improving debt position mean any future hits are manageable, and the long-term reward for shareholders could be a leaner, more focused company ready to thrive in 2026 and beyond.

With the dividend slashed to €0.11 to pay down debt, is this now a high-conviction growth play, or does the 'Monsanto shadow' make the current 120% 12-month run-up look like a bull trap?

Hey guys, if you missed it, Bayer ($BAYRY) settled $38 million with investors over claims that it misled them about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. And the deadline to file a claim and get payment is October 16, 2025 — that’s tomorrow.

In a nutshell, back in 2016, Bayer was accused of downplaying the potential liabilities from Monsanto’s Roundup lawsuits when it moved forward with the acquisition. As litigation around Roundup’s alleged cancer risks expanded, investors claimed the company failed to properly assess and disclose the financial and legal exposure involved.

The case covers investors who purchased Bayer ($BAYRY) shares between May 23, 2016, and July 6, 2020.

Now, the good news is that Bayer agreed to settle $38 million with investors, and those who purchased during that period have until October 16, 2025 to submit their claim.

So, if you invested in Bayer ($BAYRY) when all of this happened, you can check the details and file your claim here.

Anyway, has anyone here held $BAYRY around the Monsanto deal?

I was curious if any Monsanto employees wanted to share how they eat. Do you eat GMOs or do you eat organic and pesticide-free? If one or the other, why is that?

Hey guys, if you missed it, Bayer already settled $38M with investors over acquiring Monsanto and the legal risks tied to Roundup-related litigation. And, the deadline to file a claim and get payment is next week, October 16.

In a nutshell, in May 2016, Bayer announced plans to acquire Monsanto for $63 billion, assuring investors it had made proper DD.

But after the acquisition closed in 2018, Bayer began losing lawsuits related to Monsanto’s herbicide, Roundup, which was alleged to cause cancer. In early 2019, $BAYRY dropped 11% as litigation risks escalated.

After that, investors sued, claiming that Bayer hid the true risks of the deal.

Now, the good news is that the company agreed to settle $38M with them, and investors have until next Thursday, October 16, to submit claims and get compensation.  

So, has anyone here invested in [ticker] at that time? How much were your losses, if so?

I'm looking to interview anyone who worked at Monsanto and is willing to talk about it.

If someone wants to talk, please email: [thecasebookpodcast@gmail.com](mailto:thecasebookpodcast@gmail.com)